Maxigen Biotech Inc.

TWSE:1783 Stock Report

Market Cap: NT$3.9b

Maxigen Biotech Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Ching-Ting Chen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3.2yrs
CEO ownership0.1%
Management average tenureno data
Board average tenure3.3yrs

Recent management updates

Recent updates

Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings

Nov 20
Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01
We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16
Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23
The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02
Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10
Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14
Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22
If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

CEO Compensation Analysis

How has Ching-Ting Chen's remuneration changed compared to Maxigen Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

NT$155m

Jun 30 2024n/an/a

NT$147m

Mar 31 2024n/an/a

NT$150m

Dec 31 2023n/an/a

NT$166m

Sep 30 2023n/an/a

NT$191m

Jun 30 2023n/an/a

NT$192m

Mar 31 2023n/an/a

NT$163m

Dec 31 2022n/an/a

NT$139m

Sep 30 2022n/an/a

NT$110m

Jun 30 2022n/an/a

NT$99m

Mar 31 2022n/an/a

NT$87m

Dec 31 2021NT$1mNT$540k

NT$88m

Compensation vs Market: Insufficient data to establish whether Ching-Ting's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Insufficient data to compare Ching-Ting's compensation with company performance.

CEO

Ching-Ting Chen

3.2yrs

Tenure

NT$1,322,000

Compensation

Ms. Ching-Ting Chen is Institutional Director of TCI Co. Ltd. from June 25, 2024 and serves as Head of Research & Design Center since February 5, 2020. She is General manager of TCI CO., Ltd.She has been...

Board Members

NamePositionTenureCompensationOwnership
Ching-Ting Chen
GM & Representative Director3yrsNT$1.32m0.11%
NT$ 4.4m
Yung-Hsiang Lin
Chairman of the Board3.3yrsno datano data
Tsiu-Yuan Li
Representative Director9.4yrsno datano data
Chen-Chen Fu
Representative Director3.3yrsno datano data
Song Yuan Liao
Independent Director3.3yrsno datano data
Shi-Ming Li
Independent Director3.3yrsno datano data
Zeng Zhong Ming
Independent Director3.3yrsno datano data
Tsong-Jieh Chiou
Directorno datano datano data
Shih-Ming Lai
Directorno datano datano data

3.3yrs

Average Tenure

Experienced Board: 1783's board of directors are considered experienced (3.3 years average tenure).